Wilma Burdis

Attributed softer flows to accelerating Comerica outflows and seasonal tax payments, while emphasizing healthy underlying organic flows.

Walter noted Comerica was a reasonable portion of Q1 outflows with accelerated pattern expected through Q3. Jim confirmed contract finalized with all financial impacts collected. Huntington comes in Q4.

Walter indicated willingness to increase buybacks above 88% given current PE ratio, with capacity to invest in business while returning more to shareholders.

Walter confirmed 85-90% payout ratio as appropriate range going forward based on current capabilities and capital generation. Will continue opportunistic approach.

Walter noted good fundamentals on recruiting and organic growth but cautioned on seasonality. Positive on traction from recruiting and retention efforts.

Jim acknowledged combination of hot market, high sideline cash, and irrational recruiting environment. Underlying client activity remains strong with good transactions and engagement.

Jim firmly agreed overlevered competitors present future opportunity. Emphasized AMP's sound fundamentals, strong margins, and long-term focus as differentiators.

Jim noted pipeline has increased again. Packages raised to match competitive frame but focused on attracting advisers who value technology, coaching, and growth support.

Jim noted continued client interest in structured annuities and VAs without living benefits, driven by tax environment. Not playing in fixed annuity market directly.

Jim noted good Q1 recruiting, strong pipeline continuing. Packages have gotten more competitive but Ameriprise's technology and value proposition differentiate.

Jim confirmed flexibility to increase buybacks above the 80% baseline as share price and environment warrant. New authorization provides ample capacity.

Jim and Walter indicated corporate costs will be similar to Q4 levels, with severance declining and cloud transformation costs dissipating through Q1/Q2.

Walter noted G&A will be measured relative to revenue generation, with AWM expenses tied to activity/growth. Jim added AM transformation benefits carry into 2025.

Kalmbach confirmed full-year buybacks of roughly $670-700 million, front-half weighted, with pro-rata pacing across Q3 and Q4 funded partly by term-loan proceeds.

Darden said AI-driven search cut paid-search volume and bid up costs, pushing spend toward Instagram, Facebook and AI-generated ads while staying disciplined on margin.

Narrowed to $650-700M, midpoint ~$675M. Better visibility on subsidiary dividend distributions reduces downside uncertainty.

2025 statutory earnings finalized higher in range ($650-700M excess FCF). Plus opportunistic acceleration when shares dipped below $140 in Q1. Range increased to $560-610M buybacks for 2026.

Liberty and Family Heritage on track. AIL issue is compensation structure driving sales productivity over recruiting/retention, being addressed with Q2 changes. DTC guide tempered slightly due to tough H2 2025 comps. Not macro-driven: 2 of 3 agencies growing strongly, indicating company-specific issue at AIL.

Life gains from favorable mortality and lapse experience vs long-term assumptions. Expects continued remeasurement gains in 2026 even after Q3 assumption update ($50-100M). Health gains more volatile due to Med Sup rate increase mechanics, but premium rate increases should support continued positive experience.

Still more to unlock. Agency-side technology coming online in 2026-2027 to boost agent productivity. DTC marketing and targeting sophistication continuing to improve. Conversion improvement across enterprise enables expanded campaigns. Not yet at full potential.

M&A must enhance distribution and fit strategy. Stock buyback still most compelling use at current valuation. Will evaluate opportunities but nothing imminent.

Post-assumption-update baseline will be at prepandemic mortality. Current experience is below that, so continued remeasurement gains expected into 2026 if trends persist. Long-term expectation is reversion to baseline.

Post-assumption update, policy obligations run rate improves. But offsetting amortization increases from LDTI transition mean 2026 likely similar to H1 2025 range.

January softness from holiday seasonality, ramped through Q1. April agent count up 3% vs March. DTC underwriting automation expected online in H2 to boost issue rates.

CFO confirmed $550-600M organic base is reasonable, noted investment income flatness will limit upside, promised update next quarter.

Management emphasized customer resiliency through inflation cycles, noting policies are affordable ($30-60/month) and the underinsured market remains large.

Amy (pre-close, limited detail) cited expense synergies from dropping leased dental network and scaling Beam's quoting front end across the block.

Amy credited dental network optimization, the DenteMax acquisition and past pricing actions, guiding loss ratios lower into H2.

Chris explained strong Q4 2025 industry-wide ($28B) depleted Q1 pipeline. Industry anecdotally light in Q1. Q2 pipeline remains light. Pattern expected similar to 2025 with lighter first half and accelerated second half. Disciplined on returns with capital deployed elsewhere if targets not met.

Amy noted Principal was first to market with dental pricing changes 18-24 months ago which temporarily impacted sales. Now seeing competitors implement rate increases bringing business back to market. Comfortable with current pricing levels. Q1 production a good indicator for 2026 dental sales power.

Deanna described divestitures as ongoing portfolio optimization focused on higher growth, higher return businesses. Impact on revenue, AUM, capital but accretive to EPS and ROE. Now positioned to focus on growth rather than ongoing optimization.

Joel cited competitive positioning, differentiated business model, and capital-light businesses that allow organic investment plus shareholder returns. Currently at very high end of prior 14-16% range with additional improvement expected. Deanna added organic growth focus supports all metrics simultaneously.

Chris highlighted three growth areas: WSRS guaranteed account products in retirement plans, PRT with strong quarter and return discipline in smaller market segments, and RILA lifetime income products. All growing at attractive returns. Volume focus on PRT is secondary to return discipline.

Amy detailed broad-based improvement: group disability from lower LTD incidents, group life from lower frequency, dental loss ratio improved 100bp. SMB marketplace focus means better plan designs. Worksite and voluntary products growing and adding margin expansion over time.

Chris highlighted RILA sales over $500M, PRT $800M, and WSRS GA growth. Investment-only dialed down as capital deployed elsewhere at better returns.

Amy explained individual life mortality volatility driven by severity, including a single large $5M claim on a 26-year policy. Group life produced strong result.

Amy explained dental repricing due to high utilization, emphasis on disciplined profitable growth over volume. Bundled approach helps cushion dental rate increases across products.

Chris noted litigation focused on fee-backed providers, hasn't migrated to SMB. Emphasized Principal's 80-year track record and reliability.

Max Broden framed the opportunity against JPY 10.8 trillion of FSA policy reserves, noting capital freed up depends heavily on which blocks are ceded, aging, and interest rates, and pointed to the 2021 FAB.

Brad Dyslin explained the U.S. dollar portfolio hedges the economic value of Aflac Japan so FX moves offset across the balance sheet, with only a small ESR impact and ample cushion on dollar-asset gains.

Max positioned reinsurance as an add-on strategy at good IRRs that diversifies earnings and risk, not large enough to alter shareholder return commitment.

Max explained the yen-debt strategy for FX hedging, current leverage at 21.2% within 20-25% corridor, and confirmed no plans to increase leverage.

Max explained two drivers: (1) maturing US dollar assets realize FX gains from yen weakening over 5-10 year holding periods, and (2) reinsurance transactions to Bermuda release Japan reserves. Core underlying FSA earnings run at JPY 200B+ per year.

Max reiterated IRR-driven buyback philosophy unchanged. Cautioned that FSA earnings tailwind goes both ways if yen strengthens. Further reinsurance transactions would create additional FSA earnings and cash flow.

Max confirmed supplemental fixed-benefit products are not exposed to treatment cost inflation, only diagnosis frequency. Virgil added product refreshes incorporate new approved treatments.

Virgil confirmed no material operational or financial impact from data breach. Aflac continues to service customers normally.

Koide noted Japan Post Company taking conservative approach but Japan Post Insurance not directly impacted. Cancer insurance sales continuing with new product rollout.

Max confirmed 6% ceded so far with 10% internal cap unchanged. Will reassess as they approach the limit. Very pleased with outcomes including improved balance sheet efficiency and ROE.

Max explained three-component enterprise hedging program: US dollar assets in Japan, yen debt, and FX forwards, providing economic protection despite GAAP translation impact.

Sullivan summarized the difference as focus and execution, saying the biggest change is what they choose not to do, having narrowed the footprint and raised accountability through changed performance and compensation systems, citing meeting or exceeding results in 5 of the last 6 quarters.

Del Frias attributed the quarter's beat to business growth across international, retirement, Individual Life and PGIM plus the interest-rate tailwind, a non-linear POJ modeling difference, and some one-time items including the corporate-and-other loss adjustment.

Del Frias directly confirmed no expected changes to capital deployment or shareholder distributions, consistent with April 21 call messaging that POJ misconduct will not materially impact cash flows or capital position.

Del Frias clarified Prudential participates via Prismic, detailing first flow reinsurance transaction in February (MYGAs), second covering U.S. dollar Japan liabilities in Q1, and first third-party transaction with Daiichi for yen-denominated whole life and annuity block. Sullivan added PGIM manages lion's share of Prismic assets.

Andy confirmed PRT market will be softer in 2025 vs 2024 but H2 pipeline more robust. Tale of two cities: small-end strong, jumbo quieter. LRT year-to-date over $11B. U.K. $50-55B/year market, Netherlands $330B DB-to-DC reform opportunity.

Andy cited $20B+ in total 12-month inflows, $2.4B this quarter. Third-party split evenly between retail and institutional. Strong public fixed income, privates, and alternatives offset by Jennison equity outflows. Optimistic on institutional, cautious on retail.

Yanela confirmed 2025 will likely be below average within the 3-year target range due to near-term headwinds.

Rob explained the block was a good test case for the type of dollar-denominated product that the broader industry will need to address under ESR.

McCallion said a higher-rate environment favors a modest PE decline over time as distributions outpace contributions; the Q1 sale was opportunistic.

Tadros called 4% to 7% a multiyear range, citing strong sales, higher persistency and double-digit voluntary growth.

John McCallion confirmed Asia assumption review benefits (lower Japan morbidity and favorable lapse experience) are one-time in nature, not ongoing.

Eric Clurfain explained industry-wide VAT deduction change affecting only health products. Notable charges in 2025, lesser impact in 2026 (~$50-60M LatAm earnings reduction), little to no impact by 2027. Already adjusting underlying rate assumptions for annually renewable products.

John McCallion disclosed $6B mandate split between transaction-related and separate relationship-based mandates. Mostly public fixed income including some overseas assets. Declined to provide more specific detail.

John McCallion confirmed steady MIM client segment growth, differentiated product quality, strong business development pipeline, and optimism about the five-year MIM strategy.